A small, early-stage study tested a new, tiny medical device designed to be implanted in the brain. The device, which weighs less than a paperclip, continuously measures pressure inside the skull. Researchers wanted to see if it was safe and could work long-term for people with hydrocephalus, a condition where fluid builds up in the brain. The study included 10 adults and 10 children with hydrocephalus. The device was implanted and monitored both in the hospital and from patients' homes for up to 18 months. The main finding was that the device could successfully send pressure readings remotely for that entire time. In several children, the device detected rises in brain pressure that were linked to failures of their existing brain shunt, a common treatment device. Doctors reported that having this real-time data could help them make decisions about patient care. The study did not report any specific safety problems or side effects from the implant. The main reason to be careful is that this was a 'first-in-human' trial, meaning it's one of the very first times this device has been tested in people. Only 20 people were involved, and the study did not compare the device to any other monitoring method or provide detailed statistical results. Readers should understand this as a promising but very early step in medical device development. It shows the technology is possible, but much larger and more rigorous studies are required to prove it is reliably safe and truly helpful for managing hydrocephalus.
First-in-human trial shows microimplant enables remote intracranial pressure monitoring in hydrocephalusSmall study tests tiny brain implant for long-term pressure monitoring in hydrocephalus
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This first-in-human safety and initial efficacy trial evaluated a novel, implantable microimplant (0.28 g) designed for long-term intracranial pressure (ICP) monitoring within the cerebral cortex. The study enrolled 20 patients with hydrocephalus (10 adults and 10 children) in a mixed home and hospital setting, with follow-up for up to 18 months. No comparator group was specified, and primary and secondary outcomes were not formally reported.
The main findings indicate the device was capable of remote ICP monitoring in patients at home for the duration of the study. In several children, shunt failures that occurred were associated with raised ICP readings. Physicians were reportedly able to obtain real-time ICP data that could inform management changes. No specific numerical data, effect sizes, or statistical measures were provided for these observations.
Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the very small sample size, the absence of a control group, and the lack of reported statistical analysis. The study represents a preliminary proof-of-concept. While the technology shows potential for remote monitoring in a complex condition, its clinical utility, safety profile, and impact on patient outcomes remain to be established in more rigorous trials.
View Original Abstract ↓
High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants
High-Dose Vitamin D May Reduce BPD in Preterm Infants
Related in Pediatrics
From Other Specialties
